BreezeBio

BreezeBio, Inc. (legally Breeze Bio, Inc.; formerly GenEdit) is a South San Francisco, California-based biotechnology company developing genetic medicines enabled by non-viral, targeted delivery. Its proprietary NanoGalaxy platform is a library of synthetic, non-lipid hydrophilic polymer nanoparticles engineered to encapsulate and carry genetic payloads such as mRNA, siRNA and DNA, as well as CRISPR ribonucleoproteins, to selected cells and tissues. The company reports demonstrated delivery to immune cells and to tissues in the heart, lung and central nervous system, with tissue tropism governed by the physicochemical properties of the encapsulating polymers.

The company has shifted from a delivery-platform model to an internal therapeutics pipeline focused on autoimmune disease and oncology. Its lead candidate, BRZ-101, is an HNP-mRNA immune modulation therapy for type 1 diabetes that delivers mRNA-encoded autoantigens together with tolerogenic co-factors to antigen-presenting cells, which present the antigens to T cells in a tolerogenic context to induce antigen-specific regulatory T cells and anergic T cells without broad immunosuppression. In preclinical work, BRZ-101 induced antigen-specific tolerance in multiple autoimmune disease models, including the NOD mouse model of diabetes, and was reported tolerated in mice and non-human primates; the program is entering IND-enabling studies. BreezeBio is also applying the platform to in vivo CAR-T, using ligand-conjugated nanoparticles to reprogram T cells directly in the body to transiently deplete autoantibody-producing B cells in autoimmune disease and for oncology applications.

Founding story

The company was founded in 2016 by Kunwoo (Ryan) Lee, Ph.D., Hyo Min (Huey) Park, Ph.D., and Niren Murthy, Ph.D., who worked in the early period of CRISPR/Cas9 gene editing and gene therapy alongside Jennifer Doudna, Ph.D., at UC Berkeley, and later observed the emergence of mRNA therapeutics during the COVID-19 pandemic. Concluding that delivery was the limiting factor for genetic medicines, the founders took established polymer-based nanoparticle technology and added new chemistry intended to improve safety and efficacy. Following an approach used by UC Berkeley colleague and company director David Schaffer, Ph.D., they industrialized nanoparticle screening through scale, iteration and artificial intelligence in order to test greater structural diversity, which led to the NanoGalaxy platform and lead programs in autoimmune disease.

Business model

BreezeBio operates as a preclinical-stage therapeutics developer, advancing proprietary internal drug candidates built on its NanoGalaxy delivery platform while also licensing and co-developing the platform with pharmaceutical partners, as in its multi-year collaboration and license agreement with Genentech.

Disclosed sources describe partnership-based revenue: the multiyear collaboration and license agreement with Genentech, under which BreezeBio achieved an initial milestone and received an associated payment in 2025. Other funding described comes from venture financing and SBIR/STTR grants.

Traction

Closed $60 million in Series B financing in February 2026 after a $26 million Series A in 2021 and a Series A1 in January 2024. BRZ-101 has completed preclinical studies showing antigen-specific tolerance in multiple autoimmune models including the NOD mouse and reported tolerability in mice and non-human primates, and is advancing into IND-enabling studies. The company achieved and was paid an initial milestone under its Genentech collaboration in 2025, was a Phase I winner of the NIH TARGETED Challenge in 2023, and presented platform data at the ADA 2026 meeting.

Latest developments

In February 2026 the company announced its rename from GenEdit to BreezeBio together with a $60 million Series B led by Yuanta Investment and DSC Investment. In May 2026 it announced a scientific advisory board to support pipeline development, and in June 2026 it presented data supporting the NanoGalaxy platform for antigen-specific immune tolerance in type 1 diabetes at the ADA 2026 meeting. Platform expansion continues toward ligand-conjugated nanoparticles for in vivo CAR-T, and R&D activities under the Genentech collaboration are ongoing.